Evidence map›Paper›PMID 38448792›Full record

ArticleNature medicine2024

Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

Yara L Verschoor, Joris van de Haar, José G van den Berg, Johanna W van Sandick, Liudmila L Kodach, Jolanda M van Dieren, Sara Balduzzi, Cecile Grootscholten, Marieke E IJsselsteijn, Alexander A F A Veenhof and 14 more

Open access · hybridAbstract readPublished Erratum
In one paragraph

Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Current status of neoadjuvant immunotherapy for the treatment of gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 3 countries.

Yara L VerschoorDepartment of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID http://orcid.org/0009-0005-7217-1460
Joris van de Haar *Department of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-5899-3971
José G van den Berg *Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Johanna W van SandickDepartment of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Liudmila L KodachDepartment of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Jolanda M van DierenDepartment of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0003-3958-4990
Sara BalduzziBiometrics department, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0003-1205-1895
Cecile GrootscholtenDepartment of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Marieke E IJsselsteijnDepartment of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
Alexander A F A VeenhofDepartment of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Koen J HarteminkDepartment of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Marieke A VolleberghDepartment of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Adham JurdiNatera, Inc, Austin, TX, USA.ORCID http://orcid.org/0000-0002-2985-3053
Shruti SharmaNatera, Inc, Austin, TX, USA.
Erik SpickardNatera, Inc, Austin, TX, USA.ORCID http://orcid.org/0000-0002-5024-3559
Emilia C OwersDepartment of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Annemarieke Bartels-RuttenDepartment of Radiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Peggy den HartogDepartment of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Noel F C C de MirandaDepartment of Pathology, Leiden University Medical Center, Leiden, the Netherlands.ORCID http://orcid.org/0000-0001-6122-1024
Monique E van LeerdamDepartment of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-5719-3208
John B A G HaanenDepartment of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-5884-7704
Ton N SchumacherDepartment of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0003-0517-8804
Emile E VoestDepartment of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-8249-9586
Myriam ChalabiDepartment of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. m.chalabi@nki.nl.ORCID http://orcid.org/0000-0002-8607-6174
Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital · NLThe Netherlands Cancer Institute · NLLeiden University Medical Center · NLNatera (United States) · USOncode Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38448792
PMCPMC11108765
OpenAlexW4392502402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.